STOCK TITAN

Sera Prognostics, Inc. - SERA STOCK NEWS

Welcome to our dedicated page for Sera Prognostics news (Ticker: SERA), a resource for investors and traders seeking the latest updates and insights on Sera Prognostics stock.

Sera Prognostics, Inc. (NASDAQ: SERA) is a biotechnology company based in Salt Lake City, Utah, specializing in the development of innovative diagnostic tests for early prediction of preterm birth risk and other pregnancy complications. Sera's mission is to provide pivotal pregnancy information to improve maternal and neonatal health. The company's flagship product, the PreTRM® Test, offers a unique blood-based biomarker test that predicts the individualized risk of spontaneous premature delivery in asymptomatic singleton pregnancies, allowing for proactive clinical interventions.

Sera Prognostics leverages a proprietary platform integrating proteomics and bioinformatics to discover, develop, and commercialize predictive analytic products that address the unmet needs in women's health. The company is committed to enhancing prenatal care and has formed strategic partnerships, including collaboration with the Bill & Melinda Gates Foundation to make its technologies accessible in underserved regions worldwide.

As a private entity supported by a robust investor base, including renowned names like Domain Associates and InterWest Partners, Sera Prognostics has assembled an expert management team and board of directors with substantial experience in clinical development and women's healthcare diagnostics. Recent achievements include the company's addition to the preliminary list of the Russell 3000 and Russell Small-Cap 2000 indexes, reflecting its growing market presence.

Financially, Sera Prognostics reported a significant reduction in operating expenses in recent quarters, aligning its commercial strategy with current market dynamics. The company continues to focus on advancing its product pipeline, including the development of ambient whole blood collection methods to enhance lab efficiency and reduce costs. The overall strategic directives aim at broadening test adoption and improving health outcomes, ultimately reducing the healthcare costs associated with maternal and neonatal complications.

For the latest updates, financial results, and operational highlights, interested parties can access the company's investor relations page and register for upcoming conference calls.

Rhea-AI Summary

Sera Prognostics, Inc. (NASDAQ: SERA) and the Newborn Foundation have partnered to launch the Every Mother, Every Baby Project aimed at reducing maternal and neonatal mortality linked to preterm birth. This initiative focuses on educating healthcare professionals and improving access to biomarker-based tests like Sera's PreTRM® test, crucial for identifying at-risk pregnancies. The project aims for equitable health outcomes by addressing policy frameworks and ensuring standardized testing reimbursement. Over 60% of infant deaths occur during the neonatal period, with preterm birth a significant contributor.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.86%
Tags
partnership
-
Rhea-AI Summary

Sera Prognostics, Inc., the Pregnancy Company® (Nasdaq: SERA), will release its first quarter fiscal year 2022 financial results on May 10, 2022, after market close. A conference call and live webcast will follow at 5:00 p.m. ET to discuss operational highlights and financial metrics. Sera specializes in maternal and neonatal health through innovative diagnostics like the PreTRM® test, which predicts preterm birth risk. The company aims to improve pregnancy outcomes and reduce healthcare costs associated with complications of prematurity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
-
Rhea-AI Summary

Sera Prognostics announced the appointment of Dr. Jane F. Barlow to its Board of Directors, effective April 12, 2022. Dr. Barlow is recognized for her executive experience in health services and consulting, including roles as CEO of her own firm and Chief Clinical Officer at Real Endpoints. Her expertise is expected to bolster Sera's mission to enhance maternal and neonatal health with innovative diagnostics, including the PreTRM® test, which identifies preterm birth risk. CEO Gregory C. Critchfield highlighted Dr. Barlow's potential contributions towards improving healthcare outcomes and reducing costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.31%
Tags
management
Rhea-AI Summary

Sera Prognostics Inc. (SERA) reported its Q4 and full-year 2021 financial results, highlighting a revenue increase to $26,000 in Q4 2021 from $6,000 in Q4 2020 and $82,000 for the full year compared to $25,000 in 2020. Operating expenses rose significantly, totaling $12.6 million in Q4, primarily due to increased commercial operations and R&D costs. The company reported a net loss of $12.5 million for Q4 2021, up from $5.4 million in the previous year. Sera also announced new partnerships and ongoing market expansion efforts aimed at improving the adoption of its PreTRM® Test.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.65%
Tags
-
Rhea-AI Summary

Sera Prognostics (Nasdaq: SERA) presented findings at the 69th Annual Meeting of the Society for Reproductive Investigation. The study analyzed over 10,500 patients to evaluate the prediction of preeclampsia using 31 protein biomarkers and 6 clinical factors. Key results showed that previous preeclampsia was a strong predictor, while 7 biomarkers effectively predicted preeclampsia and 5 predicted preterm preeclampsia. The study highlights Sera's commitment to improving maternal health through innovative diagnostics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.45%
Tags
none
-
Rhea-AI Summary

Sera Prognostics (Nasdaq: SERA), dedicated to enhancing maternal and neonatal health, will release its fourth quarter and full year 2021 financial results on March 29, 2022, post-market close. A conference call will follow at 5:00 p.m. ET to discuss the results and operational highlights. The PreTRM® Test, a key product, predicts preterm birth risk with a focus on reducing healthcare costs associated with prematurity. The company highlights its commitment to addressing the serious issue of preterm births, which affect over one in ten infants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.45%
Tags
Rhea-AI Summary

Sera Prognostics, dedicated to enhancing maternal and neonatal health, will present at two upcoming virtual conferences: the 42nd Annual Cowen Health Care Conference on March 8, 2022, and the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022. CEO Gregory C. Critchfield will share company updates and latest achievements. The presentations will be accessible via webcast on the Sera Prognostics website. The company focuses on early prediction of preterm birth risks through its PreTRM® Test, aiming to improve healthcare outcomes for women and infants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.05%
Tags
conferences
-
Rhea-AI Summary

Sera Prognostics Inc. (Nasdaq: SERA) announced the rescheduling of its presentation at the virtual Citi 2022 Healthcare Conference, now set for February 24, 2022, at 9:30 a.m. EST. CEO Gregory C. Critchfield will provide an update and discuss recent achievements. A live webcast will be available on Sera's website, although no replay will be offered. Sera Prognostics is dedicated to enhancing maternal and neonatal health, focusing on early prediction of preterm birth risks through its PreTRM® Test, aimed at enabling proactive interventions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Sera Prognostics, the Pregnancy Company® (Nasdaq: SERA), announced its participation in two upcoming virtual investor conferences: the BTIG MedTech Conference on February 17, 2022, and the Citi 2022 Healthcare Conference on February 24, 2022. CEO Gregory C. Critchfield will provide updates on the company's innovative pregnancy biomarker solutions. Sera's PreTRM® Test offers individualized risk predictions for preterm birth. Notably, 10% of infants are born prematurely in the U.S., incurring healthcare costs of approximately $25 billion annually.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
conferences
Rhea-AI Summary

Sera Prognostics Inc. (NASDAQ: SERA) announced a new agreement with MultiPlan to enhance access to its PreTRM® Test, a blood-based biomarker test predicting the risk of preterm birth. This partnership will allow for better medical intervention through MultiPlan's extensive network of over 700 healthcare payers and 1.2 million providers. The PreTRM® Test is crucial for identifying high-risk pregnancies early, enabling personalized care plans. Sera aims to broaden adoption of this test, which is pivotal for improving maternal and neonatal health while reducing healthcare costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.67%
Tags
none

FAQ

What is the current stock price of Sera Prognostics (SERA)?

The current stock price of Sera Prognostics (SERA) is $7.95 as of November 4, 2024.

What is the market cap of Sera Prognostics (SERA)?

The market cap of Sera Prognostics (SERA) is approximately 263.9M.

What is Sera Prognostics' main product?

The main product of Sera Prognostics is the PreTRM® Test, a blood-based biomarker test for predicting the risk of preterm birth.

Where is Sera Prognostics headquartered?

Sera Prognostics is headquartered in Salt Lake City, Utah.

What is the mission of Sera Prognostics?

Sera Prognostics aims to improve maternal and neonatal health by providing early, pivotal pregnancy information to doctors and patients.

Who are some of the major investors in Sera Prognostics?

Major investors include the Bill & Melinda Gates Foundation, Domain Associates, InterWest Partners, and more.

What recent financial milestone has Sera Prognostics achieved?

Sera Prognostics has been added to the preliminary list of the Russell 3000 and Russell Small-Cap 2000 indexes.

How does the PreTRM® Test work?

The PreTRM® Test measures proteins in the blood during weeks 18-20 of pregnancy to predict the risk of spontaneous preterm birth.

What are the benefits of the PreTRM® Test?

The PreTRM® Test allows for early, individualized risk assessment of preterm birth, enabling proactive healthcare interventions to improve outcomes.

What strategic partnerships does Sera Prognostics have?

Sera Prognostics collaborates with the Bill & Melinda Gates Foundation to make its diagnostic technologies accessible in underserved regions.

What are the company's future plans for expanding its product offerings?

Sera Prognostics plans to enhance its product pipeline with new diagnostic tests and ambient whole blood collection methods to increase efficiency and reduce costs.

What challenges does Sera Prognostics face?

Challenges include achieving broad scientific and market acceptance of the PreTRM® Test, potential competition, and securing third-party payer coverage and reimbursement.

Sera Prognostics, Inc.

Nasdaq:SERA

SERA Rankings

SERA Stock Data

263.95M
32.40M
12.74%
71.37%
3.36%
Medical Devices
Services-medical Laboratories
Link
United States of America
SALT LAKE CITY